[Corrections] Correction to Lancet Diabetes Endocrinol 2019; 7: 528–39

Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019; 7: 528–39—In this Article, the mean age for the sitagliptin group in table 1 should have been 57·9 years, the first line of the fifth paragraph in the Results should have read “Estimated mean HbA1c levels at week 52 were 7·0% (SE 0·1; 53 mmol/mol [SE 1]) with oral semaglutide and 7·5% (SE 0·1; 59 mmol/mol [SE 1]) with sitagliptin for the treatment policy estimand and 6·9% (SE 0·1; 52 mmol/mol [SE 1]) versus 7·6% (SE 0·1; 60 mmol/mol [SE 1]) for the trial product estimand”, and the appendix has been updated.

Bekijk het originele bericht